Topical nanoparticulate spironolactone formulation

Details Topical nanoparticulate spironolactone formulation Topical nanoparticulate spironolactone formulation

2011-08-23

2011-08-23

Young, Shawquia (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

08003690

ABSTRACT:
The invention relates to a topical nanoparticulate spironolactone formulation comprising nanoparticles having a mean diameter, measured by a photon correlation spectroscopy, in the range of from about 300 nm to about 900 nm. The nanoparticles are incorporated into a crystalline network system comprising a dispersion of solid crystals of polar lipids, said lipids exposing their hydrophilic side outwards and their hydrophobic side inwards towards the spironolactone nanoparticles.

REFERENCES:
patent: 4011316 (1977-03-01), Barton
patent: 4801455 (1989-01-01), List et al.
patent: 4837211 (1989-06-01), Olsen et al.
patent: 4895726 (1990-01-01), Curtet et al.
patent: 5091188 (1992-02-01), Haynes
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5506222 (1996-04-01), Stefano et al.
patent: 5510118 (1996-04-01), Bosch et al.
patent: 5858410 (1999-01-01), Muller et al.
patent: 5880148 (1999-03-01), Edgar et al.
patent: 5891469 (1999-04-01), Amselem
patent: 5891845 (1999-04-01), Myers
patent: 6013637 (2000-01-01), Klein et al.
patent: 6028054 (2000-02-01), Benet et al.
patent: 6121234 (2000-09-01), Benet et al.
patent: 6180138 (2001-01-01), Engh et al.
patent: 6193985 (2001-02-01), Sonne
patent: 6228383 (2001-05-01), Hansen et al.
patent: 6294192 (2001-09-01), Patel et al.
patent: 2002/0006919 (2002-01-01), Thosar et al.
patent: 2002/0136775 (2002-09-01), Thosar et al.
patent: 2008/0069886 (2008-03-01), Vergnault et al.
patent: 0 256 285 (1988-02-01), None
patent: 0 410 348 (1991-01-01), None
patent: 0 603 405 (1994-06-01), None
patent: 03095120 (1991-04-01), None
patent: 04503800 (1992-07-01), None
patent: 04295420 (1992-10-01), None
patent: 5331066 (1993-12-01), None
patent: WO 83/00294 (1983-02-01), None
patent: WO 87/02582 (1987-05-01), None
patent: WO 96/25918 (1996-08-01), None
patent: WO 98/30360 (1998-07-01), None
patent: WO 98/31360 (1998-07-01), None
patent: WO 98/31361 (1998-07-01), None
patent: WO 99/21534 (1999-05-01), None
patent: WO 99/29300 (1999-06-01), None
patent: WO 99/40904 (1999-08-01), None
patent: WO 99/65469 (1999-12-01), None
patent: WO 00/30616 (2000-06-01), None
patent: WO 00/51572 (2000-09-01), None
patent: WO 01/37808 (2001-05-01), None
patent: WO 01/49262 (2001-07-01), None
patent: WO 02/102391 (2002-12-01), None
Schefer-Korting, et al., “Delivery of Lipophillic Compounds with Lipid Nanoparticles—Applications in Dermatics and for Transdermal Therapy,” in “Lipospheres in Drug Targets and Delivery,” CRC Press (2005) Claudio Nastruzzi, Editor.
Mehnert, et al., Advanced Drug Delivery Reviews, 47:165-196 (2001).
Muhlen, et al, European Journal of Pharmaceutics and Biopharmaceutics, 45:149-155 (1998).
Drug Bank, Spironolactone entry accessed Jan. 14, 2008.
Ralph Lane, “Overview of Fats and Oils,” (2004) accessed on Jan. 22, 2008 at http://ches.ua.edu/departments
hm/faculty/lane
hm454/McWCh11&12fats.pdf.
Kirk-Othmer Encyclopedia of Chemical Technology (2007), “Sodium Docusate” in “Gastrointestinal Agents,” p. 16, second full paragraph. Accessed Feb. 9, 2008.
2.4 Physical properties of low polar emulsifiers. edited by J. Sjoblom, (1992), Kluwer Academic Publishers, pp. 64-65.
Muller, et al. European Journal of Pharmaceutics and Biopharmaceuticals, (2000), vol. 50 pp. 161-177.
Prostate Cancer [online], retrieved on Aug. 5, 2009. Retrieved online from URL: http://www.nlm.nih.gov/medlineplus/prostatecancer.html.
da Silveira et al., “Influence of solubility and partition coefficient on the loading of combined poly(isobutylcyanoacrylate) and hydroxypropyl-β-cyclodextrin nanoparticles by steroids”,S.T.P. Pharma Sci., 10(4):309-314 (2000).
El-Shabouri, M.H., “Nanoparticles for improving the dissolution and oral bioavailability of spironolactone, a poorly-soluble drug”,S.T.P. Pharma Sci., 12(2):97-101 (2002).
Duchene et al. (1999). J. Controlled Release 62:263-268.

Affiliated with

Also associated with

Rating

Topical nanoparticulate spironolactone formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topical nanoparticulate spironolactone formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical nanoparticulate spironolactone formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2667579